重组人表皮生长因子凝胶联合赛肤润对慢性伤口患者疼痛评分 及不良反应的影响。.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Alternate Title:
      Effect of Recombinant Human Epidermal Growth Factor Gel Combined with Saifurun on Pain Scores and Adverse Reactions in Patients with Chronic Wounds.
    • Abstract:
      Objective: To investigate the effects of recombinant human epidermal growth factor (rhEGF) gel combined with Saifurun on pain scores and adverse reactions in patients with chronic wounds. Methods: A total of 108 patients with chronic wounds after gastrointestinal surgery, who were diagnosed and treated in Affiliated Hospital of Xiangnan University from March 2017 to September 2019, were chosen and were divided into combination group(n=54) and control group(n=54). The control group was given Saifurun treatment, and the combination group was given rhEGF gel treatment on the basis of the control group's therapy. The two groups were given continuous administration for 14 days, and the pain and adverse reactions were recorded. Results: The pain VAS scores on the 3rd, 7th, and 14th days after treatment of the combination group were lower than those of the control group(P<0.05). The incidence (3.7 %) of skin necrosis, wound infection, fever and other adverse reactions during treatment in the combination group was lower than that (18.5 %) in the control group (P<0.05). The wound healing rates of the combination group on the 3rd, 7th, and 14th days were 83.3 %, 96.3 % and 100.0 %, which were higher than those (59.3 %, 83.3 % and 88.9 %) of the control group (P<0.05). The serum vascular endothelial growth factor (VEGF) levels after treatment in the two groups were higher than those before treatment (P<0.05), and the combination group was higher than the control group (P<0.05). Conclusion: The application of rhEGF gel combined with Saifurun in the patients with chronic wounds can promote pain relief scores, reduce the occurrence of adverse reactions, promote the expression of VEGF, and accelerate wound healing. [ABSTRACT FROM AUTHOR]
    • Abstract:
      目的:探讨重组人表皮生长因子(Recombinant human epidermal growth factor, thEGF)凝胶联合賽肤润对慢性伤口患者疗效 反对疼痛评分与不良反应的影响。方法2017年3月-2019年9月选择在本院进行诊治的胃肠外科术后慢性伤口患者108例,根 据治疗方法分为联合组与对照组各54例。对照组给予赛肤润治疗,联合组在对照组治疗的基础上給予EGF 凝胶治疗,两组都 持续给药观察 14 d,记录患者疼痛与不良反应情况。结果:联合组治疗第3 d 第 7 d 第 14 d 的疼痛 VAS 评分都低于对照组(/0.05)。 联合组治疗期间的皮肤坏死,伤口感染、发热等不良反应发生率为3.7%,低于对照 18.5%(/<0.05)。联合组治疗后第3d伤口 愈合率为83.3%,高于对照组的59.3%(P0.05),治疗后第7d第14d的联合组伤口愈合率稍高于对照组,对比无统计学意义 (-0.05)两组治疗后的血清血管内皮生长因子(vascular endothelial growth factor,VEGF)含量高于治疗前(0.05),联合组高于对 照组(-0.05)。结论:EGF 凝胶联合賽肤润在慢性伤口患者的应用能促进缓解疼痛评分,减少不良反应的发生,促进 VEGF 的表 达,从而加快伤口愈合。 [ABSTRACT FROM AUTHOR]
    • Abstract:
      Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)